Anterior fibromuscular stroma (AFMS) is the fibromuscular (mixture of muscle and connective tissue) band-shaped structure covering the anterior surface of the prostate and is a normal anatomical component — not a true disease. It constitutes approximately 5% of the prostate volume and contains no glandular tissue. The clinical significance of AFMS is twofold: first, its distinctly hypointense appearance on T2-weighted mpMRI images can mimic anteriorly located prostate carcinoma; second, 10-20% of prostate carcinomas are anteriorly located and can develop in the AFMS or at the AFMS-transitional zone boundary — these anterior tumors are frequently missed on TRUS biopsy. In PI-RADS v2.1, AFMS is defined as a separate zone, and T2 signal, DWI/ADC, and DCE findings must be distinguished from adenocarcinoma. Although normal AFMS is T2 hypointense, it does not show diffusion restriction and does not enhance on DCE — these features are distinguishing from anterior tumor.
Age Range
20-80
Peak Age
50
Gender
Male predominant
Prevalence
Common
AFMS originates from Müllerian duct remnants and mesenchymal tissue during embryological development of the prostate. Histologically, it consists of smooth muscle fibers, collagen, and elastic fibers; it contains no glandular epithelium. This fibromuscular structure covers the anterior surface of the prostate like an armor and represents the continuation of bladder neck muscles. The T2 hypointensity of AFMS on MRI results from its dense collagen and smooth muscle fiber content — these structures have low free water content and exhibit short T2 relaxation times. Because it lacks glandular tissue, it does not produce PSA. The critically important clinical aspect of AFMS is that anterior prostate carcinomas can develop in this region: the glandular epithelium at the transitional zone-AFMS boundary may harbor adenocarcinoma foci, and these tumors frequently cannot be sampled in standard posterolateral TRUS biopsy schemes. MR-guided targeted biopsy has become the gold standard for evaluation of suspicious lesions in the AFMS region.
The absence of diffusion restriction on DWI and enhancement on DCE of the T2 hypointense structure in the anterior prostate confirms that this structure is normal AFMS. In PI-RADS v2.1, this triple assessment (T2 + DWI + DCE) is mandatory for reliable characterization of lesions in the AFMS region. Anterior adenocarcinoma shows T2 hypointensity + DWI restriction +/- DCE positivity — normal AFMS is distinguished by the absence of these two criteria.
Symmetric, thin (3-5 mm thick), band-shaped homogeneous hypointense structure on the anterior surface of the prostate on T2-weighted images. AFMS covers the anterior surface from the 11 to 1 o'clock position (clockwise). Normal AFMS is homogeneous and well-defined; asymmetry, focal thickening, nodularity, or irregularity at the posterior AFMS boundary are suspicious findings for anterior tumor. In PI-RADS v2.1, T2 hypointensity of AFMS is considered normal and does not contribute to scoring alone.
Report Sentence
A symmetric, thin band-shaped hypointense structure is observed on the anterior surface of the prostate on T2-weighted images, consistent with normal anterior fibromuscular stroma (AFMS).
Normal AFMS shows no diffusion restriction on DWI — no signal increase at high b values (b=1000-1500) and normal or mildly low ADC values on the ADC map. This finding is the most critical distinguishing feature from anterior adenocarcinoma: anterior adenocarcinoma shows marked diffusion restriction and low ADC on DWI. In PI-RADS v2.1, when DWI restriction is observed in the AFMS region, the PI-RADS score is upgraded.
Report Sentence
No diffusion restriction is observed in the anterior prostatic region on DWI, and ADC values are within normal limits — consistent with normal AFMS, no findings suggestive of anterior adenocarcinoma.
Normal AFMS shows no enhancement or minimal enhancement on dynamic contrast-enhanced MRI (DCE). As it lacks glandular tissue and dense vascular structures, contrast agent uptake is limited. When DCE positivity (early, focal enhancement) is observed in the AFMS region, anterior adenocarcinoma suspicion arises and the PI-RADS score is upgraded.
Report Sentence
No enhancement is observed in the anterior prostatic region on DCE, consistent with normal AFMS; no findings suggestive of anterior adenocarcinoma.
Asymmetric thickening, focal nodularity, or irregularity at the posterior boundary of AFMS — suspicion for anteriorly located adenocarcinoma. Normal AFMS is symmetric and thin band-shaped; focal thickening (>5 mm) or blurring of the posterior AFMS boundary with the transitional zone suggests tumor infiltration. In this case, DWI, ADC, and DCE correlation is mandatory.
Report Sentence
Focal asymmetric thickening/nodularity of the AFMS is observed in the anterior prostatic region, and anterior adenocarcinoma should be excluded with DWI and DCE correlation.
Homogeneous hypoechoic band in the anterior region of the prostate on TRUS. Normal AFMS may not be clearly visible on TRUS or may be indistinguishable from anterior prostate parenchyma. Adenocarcinoma in the AFMS is usually not visible on TRUS — this is one of the reasons anterior tumors are frequently missed on TRUS biopsy. MR-guided or MR-TRUS fusion biopsy provides superior diagnostic accuracy for anterior lesions.
Report Sentence
The anterior prostatic region has been evaluated on TRUS without significant pathological finding in the AFMS region; mpMRI is recommended if anterior lesion suspicion exists.
Criteria
Symmetric, thin band, homogeneous T2 hypointensity. DWI/ADC normal, DCE negative. ~5% of prostate volume.
Distinct Features
No clinical significance, no follow-up required. Should be described as normal anatomical structure in radiological report. Anterior stroma may thicken in BPH — normal variant.
Criteria
Focal thickening/nodularity in AFMS + DWI restriction + DCE positivity. 10-20% of all prostate carcinomas are anteriorly located. Frequently missed on TRUS biopsy.
Distinct Features
Requires MR-guided or MR-TRUS fusion biopsy. Assessed as PI-RADS 4-5. Usually Gleason 3+3 or 3+4 — aggressive subtypes rare. mpMRI critical for early diagnosis.
Criteria
Symmetric AFMS thickening proportional to prostate enlargement due to BPH. DWI/DCE negative. Does not raise adenocarcinoma suspicion.
Distinct Features
Symmetric, diffuse thickening (not focal). Other BPH findings accompany (TZ nodules, urethral compression). Confirmed benign by normal ADC values and absence of enhancement.
Distinguishing Feature
TZ adenocarcinoma shows 'erased charcoal sign' (homogeneous hypointense lenticular lesion that has erased the normal T2 heterogeneity of BPH nodules) and has DWI restriction. Normal AFMS is symmetric band-shaped and DWI/DCE negative. TZ adenocarcinoma is typically more posterior and laterally located than AFMS.
Distinguishing Feature
BPH nodules are well-circumscribed, encapsulated nodular lesions in the transitional zone and typically show heterogeneous T2 signal (glandular + stromal component). AFMS contains no glandular component and is homogeneously hypointense. BPH stromal nodules may be T2 hypointense but are located within the TZ, outside the anterior AFMS region.
Distinguishing Feature
Leiomyoma is a well-circumscribed, encapsulated, T2 hypointense solid mass frequently located in the anterior/periprostatic region. Normal AFMS is a diffuse band (not a focal mass). Leiomyoma may show mild diffusion restriction on DWI but ADC values are higher than adenocarcinoma. Leiomyoma is a rare prostatic tumor.
Urgency
routineManagement
surveillanceBiopsy
Not NeededFollow-up
no-follow-upNormal AFMS is an anatomical structure and requires no treatment or follow-up. However, the AFMS region must be carefully examined during radiological assessment to avoid missing anterior adenocarcinoma. In PI-RADS v2.1, AFMS is evaluated as a separate zone with triple assessment of T2, DWI, DCE. When suspicious findings (focal thickening + DWI restriction + DCE positivity) are detected in the AFMS region, it is reported as PI-RADS 4-5 and MR-guided or MR-TRUS fusion biopsy is recommended. Anterior tumors are missed in 30-50% of standard TRUS biopsies; therefore mpMRI pre-assessment is critically important for anterior lesions. Normal AFMS should be described in the report as 'anterior fibromuscular stroma, normal appearance'.
AFMS is a part of normal prostate anatomy with no clinical significance. Its recognition as a cancer mimicker is important for radiologists. DWI negativity and symmetric anatomical distribution safely differentiate from cancer. Biopsy should not be performed.